Circassia Pharmaceuticals PLC (CIR) Earns “Buy” Rating from Numis Securities Ltd
Circassia Pharmaceuticals PLC (LON:CIR)‘s stock had its “buy” rating restated by stock analysts at Numis Securities Ltd in a research note issued on Friday. They presently have a GBX 174 ($2.26) target price on the biopharmaceutical company’s stock. Numis Securities Ltd’s price objective suggests a potential upside of 85.85% from the company’s current price.
A number of other research firms have also recently weighed in on CIR. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 150 ($1.95) target price on shares of Circassia Pharmaceuticals PLC in a research note on Tuesday, April 25th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 120 ($1.56) target price on shares of Circassia Pharmaceuticals PLC in a research note on Tuesday. Finally, Peel Hunt reiterated an “add” rating and issued a GBX 150 ($1.95) target price on shares of Circassia Pharmaceuticals PLC in a research note on Tuesday, April 25th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Circassia Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus price target of GBX 141.50 ($1.84).
Circassia Pharmaceuticals PLC (LON:CIR) opened at 94.25 on Friday. The firm has a 50-day moving average of GBX 99.22 and a 200 day moving average of GBX 92.53. Circassia Pharmaceuticals PLC has a 12-month low of GBX 78.45 and a 12-month high of GBX 278.60. The company’s market capitalization is GBX 268.26 million.
COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/26/circassia-pharmaceuticals-plc-cir-earns-buy-rating-from-numis-securities-ltd.html.
About Circassia Pharmaceuticals PLC
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.